Clinical Trials Directory

Trials / Completed

CompletedNCT04412161

Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP

Retrospective Cohort Study-Analysis of LT Patients With HCC (Maximum Tumor Diameter > 6 cm).

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
Inonu University · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Retrospective data on 50 prospectively-collected HCC patients with beyond-Milan criteria with \>6cm tumors were analyzed. 5-year OS of 76.2% was found in patients with both AFP \<200 ng/ml and GGT \<104 IU/mL with tumors less than 10 cm diameter. Thus, GGT values add to AFP in patient prognosis.

Detailed description

Background:A retrospective analysis was performed of prospectively-collected transplant data on outcomes of patients with large size HCCs,to examine possible prognostically-useful factors.Methods:A total of 50 patients having tumors greater than 6cm maximum diameter were identified. Their survival and full clinical characteristics were examined, with respect to serum AFP and GGT levels.Results:Using ROC analysis, cutoff values of AFP 200 ng/ml and GGT 104 IU/ml were identified and used in this study. Significantly longer overall-survival and disease-free-survival were found for patients who had lower values of either parameter, compared with higher values.Even greater differences in survival were found when the 2 parameters were combined, with best survival (5-year OS of 76,2% versus 0%, p=0.002).The most consistent clinical correlates for these longer survivals were degree of tumor differentiation and absence of microscopic portal venous invasion.Two tumor size bands were identified,to search for the limits of this approach with larger tumors, namely 6-10 and \>10cm.Combination parameters in 6-10cm band reflected 5-year OS of 76,2% vs. 0%,in patients with low AFP plus low GGT vs. other groups.Beyond 10cm,no patients had low AFP plus low GGT.Conclusions:AFP and GGT,both singly and together, represent a simple prognostic identifier for patients with large size HCCs being treated by liver transplantation.

Conditions

Interventions

TypeNameDescription
PROCEDURELiver transplantationLiving donor liver transplantation

Timeline

Start date
2006-04-19
Primary completion
2019-01-01
Completion
2019-12-01
First posted
2020-06-02
Last updated
2020-06-02

Source: ClinicalTrials.gov record NCT04412161. Inclusion in this directory is not an endorsement.